Courtney DiNardo, MD, MSCE

This segment shifts toward the broader excitement in AML therapeutics beyond induction paradigms, focusing on emerging triplet strategies, fully oral regimens, and longer-term survival improvements demonstrated in recent clinical trials.

Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, highlight other key AML data from the 2025 ASH Annual Meeting.

Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, discuss potential dose modification approaches for the use of triplet therapy in AML.

This segment describes a foundational point in AML management: despite rapid advancements in lower-intensity therapies, intensive chemotherapy remains essential for certain biologically favorable AML subsets.

A critical question is when in the treatment timeline therapeutic intensification should occur: during induction or post-remission.

Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, discuss potential treatment strategies in AML following triplet therapy and transplant.

The experts discuss application of mutation-driven treatment approaches to younger, fit patients with AML and clarify where current low-intensity paradigms do and do not apply.

Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, discuss potential triplet strategies with menin inhibitors for KMT2A-rearranged AML.

This segment discusses the promise of triplet regimens and how emerging data may reshape AML induction in select populations.

Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, discuss data for venetoclax plus azacitidine vs induction chemotherapy in newly diagnosed, fit AML.

Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, detail populations in AML that could derive benefit from triplet therapies.

Segment 5 explores more deeply the clinical implications of CP-based regimens and how they compare with venetoclax-based therapy when preparing patients with AML for allogeneic transplant. The

Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, discuss data from MD Anderson Cancer Center on triplet therapies in AML with IDH mutations.

Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, discuss the rationale for investigating triplet therapies in acute myeloid leukemia.

Segment 4 examines how clinicians navigate transplant eligibility and early treatment choices in AML, particularly during the first days of diagnosis when critical decisions must be made without complete molecular information.

The experts explore how clinicians personalize induction therapy in AML by assessing patient fitness, biological risk factors, and early treatment response.

This segment concludes by acknowledging ongoing research efforts aimed at refining venetoclax use, such as optimizing duration, identifying predictive biomarkers, and integrating the drug with targeted therapies, to further improve outcomes while minimizing toxicity.

Throughout this segment, the panel frames the broader conversation: AML therapy is becoming more nuanced and personalized, but clinicians must navigate increasingly complex decision-making.

Panelists discuss how the future treatment landscape for myelodysplastic syndromes (MDS) appears promising with several ongoing clinical trials exploring novel combinations and targeted therapies, including investigations of venetoclax combinations, magrolimab, sabatolimab, and other immune-based approaches that could potentially improve outcomes across different risk groups and molecular subtypes.

Panelists discuss how treatment strategies for myelodysplastic syndromes (MDS) are fundamentally guided by risk stratification, with lower-risk patients typically receiving supportive care and less intensive treatments focused on quality of life and symptom management while intermediate- to high-risk patients require more aggressive approaches, including hypomethylating agents and consideration for stem cell transplantation, with emerging data supporting novel combinations and targeted therapies across the risk spectrum.

Panelists discuss how oral decitabine/cedazuridine demonstrated meaningful clinical activity in patients with TP53-mutated myelodysplastic syndromes (MDS), with a 31% complete response rate and 16.1-month median overall survival, representing an important treatment advance for this traditionally poor-prognosis molecular subgroup.

Panelists discuss how oral decitabine/cedazuridine showed encouraging efficacy in patients with myelodysplastic syndromes (MDS) with TP53 mutations, suggesting this oral formulation could be particularly beneficial for this historically difficult-to-treat molecular subgroup.

Panelists discuss how the ASCERTAIN trial demonstrated that oral decitabine plus cedazuridine provided comparable efficacy to injectable decitabine.

Panelists discuss how hypomethylating agents remain the cornerstone of therapy for intermediate to high-risk patients with myelodysplastic syndromes (MDS).

Panelists discuss how the primary therapeutic goals for patients with intermediate- to high-risk myelodysplastic syndromes (MDS) focus on extending survival and modifying disease course through intensive treatments like hypomethylating agents or stem cell transplantation while addressing unique challenges such as treatment resistance, poor response durability, and limited options after hypomethylating agents failure.

The panelists discuss the newest risk stratification tool, IPSS-M.

Courtney D. DiNardo, MD, MSCE, discusses the significance of the FDA approval of ivosidenib in patients with relapsed/refractory, IDH1-mutated myelodysplastic syndromes.

Courtney DiNardo, MD, MSCE, discusses triplets that serve as alternatives to standard-of-care approaches with azacitidine and venetoclax doublet therapy in select patients with acute myeloid leukemia.

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss the scientific achievements they have witnessed in the field of leukemia and their hopes for the future of treating this disease.

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss how they turned career obstacles into opportunities and what they have learned from being women in the leukemia field.